title: [VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma--a study of efficacy and safety, final report].
abstract: We experienced the VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) combination regimen for the treatment of elderly patients with aggressive non-Hodgkin lymphoma (NHL) in a multicenter study by 6 collaborative institutions. Patients were previously untreated > or = 60 years of age and received prophylactic G-CSF. Twenty patients entered this trial, and all of them were evaluated for feasibility, toxicity, and efficacy. The complete remission rate was 75.0%, with a 100% overall response rate; overall survival (OS) rate at 3 years was 79.1% (median follow up 761.5 days), with a 60.7% progression-free 3-year survival (PFS) rate (median follow-up 600.0 days). Our trial was promising and well-tolerated. According to IPI, high/high-intermediate risk was associated with significantly worse OS and PFS than low/low-intermediate risk (2-year OS: 51.8% versus 100.0%, p=0.0118; 2-year PFS: 33.3% versus 80.0%, p=0.0125). Grade 3/4 infections occurred in 3 patients, but no patients experienced it with predonisolone reduced.
authors.affiliation: Dept. of Hematology, Kishiwada City Hospital.
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Ishii
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Takashi
authors.initials: T
authors.lastname: Shigeki
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kitayama
authors.forename: Kunio
authors.initials: K
authors.lastname: Hayashi
authors.forename: Asao
authors.initials: A
authors.lastname: Hirose
authors.forename: Tadanobu
authors.initials: T
authors.lastname: Ohta
authors.forename: Atsuko
authors.initials: A
authors.lastname: Mugitani
authors.forename: Hiroko
authors.initials: H
authors.lastname: Fujino
authors.forename: Toshiya
authors.initials: T
authors.lastname: Yagi
authors.forename: Manabu
authors.initials: M
authors.lastname: Hirai
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Teshima
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Katsurada
authors.forename: Fumiaki
authors.initials: F
authors.lastname: Urase
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kitajima
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005240:Feasibility Studies; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D009503:Neutropenia / Q000139:chemically induced; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D001761:Bleomycin; D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; D008942:Mitoxantrone; D011241:Prednisone